Pharvaris N.V. (NASDAQ:PHVS) Receives $32.60 Average PT from Analysts

Pharvaris N.V. (NASDAQ:PHVS) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $37.1667.

Several equities analysts have recently issued reports on the company. HC Wainwright assumed coverage on Pharvaris in a report on Wednesday. They issued a “buy” rating and a $60.00 price objective for the company. Zacks Research raised Pharvaris from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $16.00 to $27.00 in a report on Thursday, October 9th. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a report on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th.

Hedge Funds Weigh In On Pharvaris

Institutional investors and hedge funds have recently modified their holdings of the business. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Pharvaris in the 2nd quarter valued at about $57,000. JPMorgan Chase & Co. increased its stake in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Palumbo Wealth Management LLC increased its stake in shares of Pharvaris by 38.0% in the 1st quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company’s stock valued at $221,000 after purchasing an additional 3,881 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Pharvaris by 9.8% in the 2nd quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock valued at $247,000 after purchasing an additional 1,257 shares in the last quarter.

Pharvaris Stock Performance

Shares of PHVS opened at $21.86 on Tuesday. The stock has a 50-day moving average of $23.01 and a two-hundred day moving average of $19.31. Pharvaris has a one year low of $11.51 and a one year high of $26.33. The stock has a market cap of $1.14 billion, a P/E ratio of -6.51 and a beta of -2.77.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07). Analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.